Skip to main content

Allo vs Hypomethylating / Best Supportive Care in MDS (BMT CTN 1102)

Trial Status: Active

This study is designed as a multicenter trial, with biological assignment to one of two study arms; Arm 1: Reduced intensity conditioning allogeneic hematopoietic cell transplantation (RIC-alloHCT), Arm 2: Non-Transplant Therapy / Best Supportive Care.

Inclusion Criteria

  • Patients fulfilling the following criteria will be eligible for entry into this study:
  • Patients with de novo MDS who have, or have previously had, Intermediate-2 or High risk disease as determined by the International Prognostic Scoring System (IPSS). Current Intermediate-2 or High risk disease is NOT a requirement.
  • Patients must have an acceptable MDS subtype:
  • Refractory cytopenia with unilineage dysplasia (RCUD) (includes refractory anemia (RA))
  • Refractory anemia with ringed sideroblasts (RARS)
  • Refractory anemia with excess blasts (RAEB-1)
  • Refractory anemia with excess blasts (RAEB-2)
  • Refractory cytopenia with multilineage dysplasia (RCMD)
  • Myelodysplastic syndrome with isolated del(5q) (5q-syndrome)
  • Myelodysplastic syndrome (MDS), unclassifiable
  • Patients must have fewer than 20% marrow blasts within 60 days of consent.
  • Patients may have received prior therapy for the treatment of MDS, including but not limited to: growth factor, transfusion support, immunomodulatory (IMID) therapy, DNA hypomethylating therapy, or cytotoxic chemotherapy prior to enrollment.
  • Age 50.0-75.0 years.
  • Karnofsky performance status > 70 or Eastern Cooperative Oncology Group (ECOG) ≤
  • 7. Patients are eligible if no formal unrelated donor search has been activated prior to date of consent. A formal unrelated donor search begins at the time at which samples are requested from potential National Marrow Donor Program (NMDP) donors. Patients who have started a sibling donor search or who have found a matched sibling donor are eligible.
  • Patients and physicians must be willing to comply with treatment assignment:
  • No intent to proceed with alloHCT using donor sources not specified in this protocol, including human leukocyte antigen (HLA)-mismatched related or unrelated donors (< 6/6 HLA related matched or < 8/8 HLA unrelated matched) or umbilical cord blood unit(s).
  • No intent to use myeloablative conditioning regimens.
  • Intent to proceed with RIC alloHCT if a matched sibling or matched unrelated donor is identified. There is no requirement as to the timing of the transplantation.
  • Patients must be considered to be suitable RIC alloHCT candidates at the time of enrollment based on medical history, physical examination, and available laboratory tests. Specific testing for organ function is not required for eligibility but, if available, these tests should be used to judge eligibility.
  • Signed informed consent

Exclusion Criteria

  • Patients with the following will be ineligible for registration onto this study:
  • Therapy-related MDS (defined as the occurrence of MDS due to prior exposure to systemic chemotherapy and/or radiation for malignancy)
  • Current or prior diagnosis of AML
  • Chronic myelomonocytic leukemia or myelodysplastic/myeloproliferative neoplasm (unacceptable MDS subtypes); uncontrolled bacterial, viral or fungal infection (currently taking medication and with progression or no clinical improvement) at time of enrollment.
  • Patients with prior malignancies, except treated non-melanoma skin cancer or treated cervical carcinoma in situ. Cancer treated with curative surgery without chemotherapy/radiation therapy > 5 years previously will be allowed. Cancer treated with curative surgery < 5 years previously will not be allowed unless approved by the Protocol Officer or one of the Protocol Chairs.
  • Prior autologous or allogeneic HCT
  • Human Immunodeficiency Virus (HIV) infection
  • Patients of childbearing potential unwilling to use contraceptive techniques
  • Patients with psychosocial conditions that would prevent study compliance

Florida

Tampa
Moffitt Cancer Center
Status: CLOSED_TO_ACCRUAL

Georgia

Atlanta
Emory University Hospital / Winship Cancer Institute
Status: CLOSED_TO_ACCRUAL
Contact: Martha Lucia Arellano

Illinois

Chicago
University of Chicago Comprehensive Cancer Center
Status: ACTIVE

Kansas

Westwood
University of Kansas Hospital-Westwood Cancer Center
Status: CLOSED_TO_ACCRUAL

Kentucky

Lexington
University of Kentucky / Markey Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Roger H. Herzig

Maryland

Baltimore
Johns Hopkins University / Sidney Kimmel Cancer Center
Status: WITHDRAWN
Contact: Margaret Mary Showel
University of Maryland / Greenebaum Cancer Center
Status: ACTIVE
Contact: Sunita Philip
Phone: 410-328-8199

Massachusetts

Boston
Brigham and Women's Hospital
Status: ACTIVE
Dana-Farber Cancer Institute
Status: ACTIVE
Massachusetts General Hospital Cancer Center
Status: ACTIVE

Michigan

Detroit
Wayne State University / Karmanos Cancer Institute
Status: CLOSED_TO_ACCRUAL
Contact: Voravit Ratanatharathorn

Missouri

Saint Louis
Siteman Cancer Center at Washington University
Status: CLOSED_TO_ACCRUAL
Contact: Peter Westervelt
Phone: 314-454-8306

New York

Buffalo
Roswell Park Cancer Institute
Status: CLOSED_TO_ACCRUAL_AND_INTERVENTION
New York
Icahn School of Medicine at Mount Sinai
Status: CLOSED_TO_ACCRUAL
Memorial Sloan Kettering Cancer Center
Status: ACTIVE
Contact: Roni Tamari

North Carolina

Chapel Hill
UNC Lineberger Comprehensive Cancer Center
Status: ACTIVE
Durham
Duke University Medical Center
Status: ACTIVE
Contact: Mitchell Eric Horwitz
Winston-Salem
Wake Forest University Health Sciences
Status: CLOSED_TO_ACCRUAL

Ohio

Cleveland
Case Comprehensive Cancer Center
Status: ACTIVE
Contact: Hillard Michael Lazarus
Columbus
Ohio State University Comprehensive Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Sumithira Vasu
Phone: 614-293-8196

Oregon

Portland
OHSU Knight Cancer Institute
Status: ACTIVE
Contact: Richard T. Maziarz

Pennsylvania

Philadelphia
University of Pennsylvania / Abramson Cancer Center
Status: CLOSED_TO_ACCRUAL_AND_INTERVENTION

Tennessee

Nashville
Vanderbilt University / Ingram Cancer Center
Status: ACTIVE

Texas

Houston
Baylor College of Medicine / Dan L Duncan Comprehensive Cancer Center
Status: CLOSED_TO_ACCRUAL
M D Anderson Cancer Center
Status: ACTIVE
Contact: Betul Oran

Utah

Salt Lake City
Huntsman Cancer Institute / University of Utah
Status: ACTIVE
Contact: Tibor J. Kovacsovics

Virginia

Richmond
Virginia Commonwealth University / Massey Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: John Michael McCarty
Phone: 804-828-4596

Washington

Seattle
Fred Hutch / University of Washington Cancer Consortium
Status: CLOSED_TO_ACCRUAL
Contact: Bart Lee Scott

Wisconsin

Milwaukee
Medical College of Wisconsin
Status: ACTIVE
Contact: Wael Saber

Background: MDS is a clonal disorder of hematopoietic precursors and stem cells, which may evolve to a terminal phase resembling acute leukemia. A subject of clinical urgency for researchers, clinicians, patients, and health care underwriters such as Medicare, is the role of allogeneic hematopoietic cell transplantation (alloHCT) in the treatment of older patients with higher risk myelodysplastic syndromes (MDS). The use of reduced intensity conditioning (RIC) regimens has extended HCT to the care of older patients with acute myelogenous leukemia (AML) and lymphoma and a number of retrospective and phase II trials for patients with MDS now show the curative potential of RIC alloHCT in selected patients. This protocol is designed to evaluate the relative benefits of RIC alloHCT compared to non-transplant therapies focusing on overall survival. This will be done by having patients biologically assigned to the alloHCT arm or the hypomethylating therapy/best supportive care arm and following them for survival at 3 years.

Trial Phase Phase NA

Trial Type Not provided by clinicaltrials.gov

Lead Organization
Medical College of Wisconsin

  • Primary ID BMTCTN1102
  • Secondary IDs NCI-2015-00858, 2U10HL069294-11, 5U24CA076518, NCI-2014-00100, NCI-2015-00326
  • Clinicaltrials.gov ID NCT02016781